NO20062300L - Fremgangsmater og reagenser for behandling av inflammatoriske forstyrelser - Google Patents

Fremgangsmater og reagenser for behandling av inflammatoriske forstyrelser

Info

Publication number
NO20062300L
NO20062300L NO20062300A NO20062300A NO20062300L NO 20062300 L NO20062300 L NO 20062300L NO 20062300 A NO20062300 A NO 20062300A NO 20062300 A NO20062300 A NO 20062300A NO 20062300 L NO20062300 L NO 20062300L
Authority
NO
Norway
Prior art keywords
treatment
reagents
methods
inflammatory disorders
compound
Prior art date
Application number
NO20062300A
Other languages
English (en)
Inventor
Edward Roydon Jost-Price
Brendan Smith
Benjamin A Auspitz
Palaniyandi Manivasakam
Michael S Slavonic
Original Assignee
Combinatorx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Combinatorx Inc filed Critical Combinatorx Inc
Publication of NO20062300L publication Critical patent/NO20062300L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Oppfinnelsen omfatter en fremgangsmåte for behandling av en immunoinflammatorisk administrering av en forbindelse med formel (1), f.eks. ibudilast eller KC-764, alene eller i kombinasjon med et kortikosteroid, tetrasubstituert pyrimidopyrimidin eller annen forbindelse. Oppfinnelsen angår også farmasøytiske blandinger omfattende kombinasjonen ovenfor for behandling eller forebygging av en immuninflammatorisk forstyrrelse.
NO20062300A 2003-11-21 2006-05-22 Fremgangsmater og reagenser for behandling av inflammatoriske forstyrelser NO20062300L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52411703P 2003-11-21 2003-11-21
PCT/US2004/038512 WO2005051293A2 (en) 2003-11-21 2004-11-17 Methods and reagents for the treatment of inflammatory disorders

Publications (1)

Publication Number Publication Date
NO20062300L true NO20062300L (no) 2006-08-21

Family

ID=34632866

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062300A NO20062300L (no) 2003-11-21 2006-05-22 Fremgangsmater og reagenser for behandling av inflammatoriske forstyrelser

Country Status (17)

Country Link
US (2) US7709495B2 (no)
EP (1) EP1689390B1 (no)
JP (1) JP2007512337A (no)
KR (1) KR20060120208A (no)
CN (1) CN1905870A (no)
AT (1) ATE497763T1 (no)
AU (1) AU2004292445B2 (no)
BR (1) BRPI0416812A (no)
CA (1) CA2546347A1 (no)
DE (1) DE602004031356D1 (no)
IL (1) IL175781A0 (no)
NO (1) NO20062300L (no)
NZ (1) NZ547389A (no)
RU (1) RU2006121978A (no)
SG (1) SG148198A1 (no)
WO (1) WO2005051293A2 (no)
ZA (1) ZA200604253B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2546347A1 (en) * 2003-11-21 2005-06-09 Combinatorx, Incorporated Methods and reagents for the treatment of inflammatory disorders
JP4954085B2 (ja) 2004-12-06 2012-06-13 メディシノバ， インコーポレイテッド 神経障害性疼痛及びその関連する症状を治療するためのイブジラスト
PL1719507T3 (pl) 2005-04-13 2010-12-31 Cipher Pharmaceuticals Inc Agoniści receptora beta2-adrenergicznego do leczenia chorób tkanki łącznej skóry
EP1971348A2 (en) * 2005-12-20 2008-09-24 Tika Läkemedel AB Systems and methods for the delivery of corticosteroids having an increased lung deposition
WO2007089617A2 (en) * 2006-01-26 2007-08-09 Combinatorx, Incorporated Methods, compositions, and kits for the treatment of musculoskeletal disorders and symptoms associated therewith
CA2653345A1 (en) * 2006-05-31 2007-12-13 Avigen, Inc. Ibudilast for inhibiting macrophage migration inhibitory factor (mif) activity
CA2654498A1 (en) 2006-06-06 2007-12-21 Avigen, Inc. Substituted pyrazolo[1,5-.alpha.]pyridine compounds and their methods of use
US7536799B2 (en) * 2007-06-07 2009-05-26 Keson Industries Chalk line apparatus with strategically located chalk fill opening
US20090005358A1 (en) * 2007-06-26 2009-01-01 Jan Lessem Compositions and methods for treating medical conditions
AU2008275148A1 (en) * 2007-07-11 2009-01-15 Medicinova, Inc. Treatment of progressive neurodegenerative disease with ibudilast
GB201305714D0 (en) 2013-03-28 2013-05-15 Ucl Business Plc Method
RU2536274C1 (ru) * 2013-12-20 2014-12-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Тверская государственная медицинская академия" Министерства здравоохранения Российской Федерации Способ лечения бородавок
CN108033959A (zh) * 2018-01-29 2018-05-15 山东省药学科学院 一种异丁司特的化学合成方法
US20210205329A1 (en) * 2018-05-21 2021-07-08 The University Of North Carolina At Chapel Hill Methods of inhibiting proinflammatory neuroimmune signaling and treating inflammatory disorders
CN113456618A (zh) * 2020-03-31 2021-10-01 天津金耀集团有限公司 一种复方双嘧达莫的吸入制剂及其制备方法
EP4132521A1 (en) * 2020-04-06 2023-02-15 MediciNova, Inc. Methods of reducing plasma level of macrophage migratory inhibitory factor in patients with ibudilast
WO2022164948A1 (en) * 2021-01-29 2022-08-04 Medicinova, Inc. Methods of treating chemical gas exposure
CN115414354A (zh) * 2022-08-29 2022-12-02 西南医科大学 花椒毒素在制备治疗血小板减少症药物中的应用

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US532248A (en) 1895-01-08 powell
JPS5229318B2 (no) 1972-03-30 1977-08-01
US4097483A (en) 1974-11-01 1978-06-27 Kyorin Pharmaceutical Co., Ltd. Pyrazolo 1,5-a!pyridines
FI65914C (fi) 1978-03-07 1984-08-10 Sandoz Ag Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a
JPS59167590A (ja) 1983-03-14 1984-09-21 Kyorin Pharmaceut Co Ltd ピラゾロ〔１，５−ａ〕ピリジン誘導体、その製法及びそれを含有する治療剤
US4894366A (en) 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
US5639724A (en) 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
US5254562A (en) 1984-12-03 1993-10-19 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
JP2577049B2 (ja) 1987-06-04 1997-01-29 三共株式会社 シクロスポリン製剤
US4925849A (en) 1987-06-15 1990-05-15 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutically useful pyrazolopyridines
JPH01153634A (ja) * 1987-12-10 1989-06-15 Kyorin Pharmaceut Co Ltd 吸入剤
US5342625A (en) 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
KR0148748B1 (ko) 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
US6007840A (en) 1988-09-16 1999-12-28 Novartis Ag Pharmaceutical compositions comprising cyclosporins
US5208228A (en) 1989-11-13 1993-05-04 Merck & Co., Inc. Aminomacrolides and derivatives having immunosuppressive activity
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5143918A (en) 1990-10-11 1992-09-01 Merck & Co., Inc. Halomacrolides and derivatives having immunosuppressive activity
US5626863A (en) 1992-02-28 1997-05-06 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5162334A (en) 1991-05-13 1992-11-10 Merck & Co., Inc. Amino O-alkyl, O-alkenyl and O-alkynlmacrolides having immunosuppressive activity
US5262533A (en) 1991-05-13 1993-11-16 Merck & Co., Inc. Amino O-aryl macrolides having immunosuppressive activity
US5250678A (en) 1991-05-13 1993-10-05 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylmacrolides having immunosuppressive activity
US5189042A (en) 1991-08-22 1993-02-23 Merck & Co. Inc. Fluoromacrolides having immunosuppressive activity
US5208241A (en) 1991-09-09 1993-05-04 Merck & Co., Inc. N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n-alkynylheteroarylmacrolides having immunosuppressive activity
CZ188394A3 (en) * 1992-02-07 1996-02-14 Albert M Kligman Pharmaceutical preparation for the control of inflammatory dermatose cleaning and the use of corticosteroidal matter in combination with a retoidal matter for preparing such preparations
US5284840A (en) 1992-06-12 1994-02-08 Merck & Co., Inc. Alkylidene macrolides having immunosuppressive activity
US6022852A (en) 1993-10-22 2000-02-08 Hexal Ag Pharmaceutical composition containing cyclosporin A
US5693648A (en) 1994-09-30 1997-12-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynyl-macrolides having immunosuppressive activity
US5688808A (en) 1994-12-22 1997-11-18 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
EP0833622B8 (en) 1995-06-12 2005-10-12 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
JPH0920663A (ja) * 1995-07-07 1997-01-21 Teikoku Seiyaku Co Ltd イブジラストを含有する徐放性細粒剤およびその製法
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
JPH11222425A (ja) * 1997-10-27 1999-08-17 Ss Pharmaceut Co Ltd 関節疾患治療用関節内投与製剤
US6372779B1 (en) 1997-12-29 2002-04-16 Ortho Pharmaceutical Corporation Anti-inflammatory compounds
US5900249A (en) 1998-02-09 1999-05-04 Smith; David J. Multicomponent pain relief topical medication
US6380207B2 (en) 1998-02-13 2002-04-30 Abbott Laboratories Glucocortiocoid-selective antiinflammatory agents
US6506766B1 (en) 1998-02-13 2003-01-14 Abbott Laboratories Glucocortiocoid-selective antinflammatory agents
EP1106178B1 (en) * 1998-08-10 2004-11-24 Kyorin Pharmaceutical Co., Ltd. Use of ibudilast for the manufacture of a medicament for treating multiple sclerosis
AU2354700A (en) * 1998-12-11 2000-06-26 Biomira Inc. Muc-1 antagonists and methods of treating immune disorders
JP2000212021A (ja) * 1999-01-14 2000-08-02 Pola Chem Ind Inc 皮膚外用剤
BR0010138B1 (pt) 1999-04-30 2012-12-11 moduladores de receptores de glicocorticóides.
JP2002544210A (ja) * 1999-05-14 2002-12-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 炎症で仲介される感染症に対する抗炎症性治療方法
US6593480B2 (en) 1999-09-01 2003-07-15 Abbott Laboratories Glucocorticoid receptor antagonists for treatment of diabetes
IL146057A (en) 2000-10-27 2007-09-20 Pfizer Prod Inc A process for the preparation of modulators of a non-steroidal glucocorticoid receptor
EP1201649B1 (en) 2000-10-28 2006-05-31 Pfizer Products Inc. Glucocorticoid receptor modulators
JP2003055220A (ja) * 2001-08-09 2003-02-26 Taisho Pharmaceut Co Ltd イブジラスト含有眼科用組成物
JP2003055222A (ja) * 2001-08-16 2003-02-26 Rohto Pharmaceut Co Ltd 安定化された組成物
EP1467730A4 (en) 2002-01-22 2010-03-10 Univ California Non-steroid ligands for the glucocorticoid receptor, compositions and uses thereof
TW200522932A (en) * 2003-09-15 2005-07-16 Combinatorx Inc Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
TW200517114A (en) * 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
CA2546347A1 (en) * 2003-11-21 2005-06-09 Combinatorx, Incorporated Methods and reagents for the treatment of inflammatory disorders

Also Published As

Publication number Publication date
EP1689390A2 (en) 2006-08-16
US20100210606A1 (en) 2010-08-19
US20050187203A1 (en) 2005-08-25
AU2004292445B2 (en) 2010-02-04
RU2006121978A (ru) 2007-12-27
CN1905870A (zh) 2007-01-31
ZA200604253B (en) 2007-10-31
NZ547389A (en) 2009-11-27
EP1689390B1 (en) 2011-02-09
AU2004292445A1 (en) 2005-06-09
US7709495B2 (en) 2010-05-04
CA2546347A1 (en) 2005-06-09
SG148198A1 (en) 2008-12-31
KR20060120208A (ko) 2006-11-24
WO2005051293A2 (en) 2005-06-09
EP1689390A4 (en) 2008-03-12
WO2005051293A3 (en) 2006-03-02
DE602004031356D1 (de) 2011-03-24
BRPI0416812A (pt) 2007-03-06
IL175781A0 (en) 2008-04-13
JP2007512337A (ja) 2007-05-17
ATE497763T1 (de) 2011-02-15

Similar Documents

Publication Publication Date Title
NO20062300L (no) Fremgangsmater og reagenser for behandling av inflammatoriske forstyrelser
CY1116754T1 (el) Παραγωγα νιτροκατεχολης ως αναστολεις της comt
CY1120384T1 (el) Απταμερη θεραπευτικα χρησιμα στην αντιμετωπιση των σχετικων με το συμπληρωμα διαταραχων
TW200517114A (en) Methods and reagents for the treatment of immunoinflammatory disorders
SG146653A1 (en) Methods and reagents for the treatment of immunoinflammatory disorders
NO20050807L (no) Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
CY1115745T1 (el) Συνθεσεις και μεθοδοι για αντιμετωπιση ή προληψη σχετιζομενης με οξαλικα νοσου
UA118645C2 (uk) Спосіб комбінованої терапії раку наночастинками, що містять рапаміцин і альбумін
EA200700333A1 (ru) Терапевтические применения ингибиторов rtp801
NO20083240L (no) Sammensetninger og fremgangsmater for forebygging og behandling av kakeksia
CY1112238T1 (el) Αναστολεις μιτωτικης κινεσινης και μεθοδοι χρησης αυτων
DK1651161T3 (da) Farmaceutiske præparater og fremgangsmåder til at fremme sårheling
BRPI0512500A (pt) tratamento ou condições envolvendo desmielinação
BRPI0508254A (pt) métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos
DE602004032522D1 (de) Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung
DK1948155T3 (da) Farmaceutiske præparater omfattende droxidopa
TW200740441A (en) Methods and reagents for the treatment of inflammatory disorders
NO20052999L (no) Ny synergistisk kombinasjon omfattende roflumilast og formoterol
EA200801120A1 (ru) Нафтильные производные в качестве ингибиторов агрегирования бета-амилоида
TW200507840A (en) Method of treating multiple myeloma
ATE466595T1 (de) Verbindungen und methoden für das downregulating der effekte von tgf-beta
SG148186A1 (en) Methods and reagents for the treatment of inflammatory disorders
DE602004011494D1 (de) Synergistische kombination enthaltend roflumilast und einen anticholinergischen wirkstoff ausgewählt aus tiotropiumsalzen für die behandlung von atemwegserkrankungen
TW200716561A (en) P38 inhibitors and methods of use thereof
CY1110368T1 (el) Συνεργιστικος συνδυασμος ο οποιος περιλαμβανει ροφλουμιλαστη και (r,r)-φορμοτερολη

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application